© 2003 by Oxford University Press
© 2003 Oxford University Press
ARTICLE |
Randomized Phase III Trial of Paclitaxel, Etoposide, and Carboplatin Versus Carboplatin, Etoposide, and Vincristine in Patients With Small-Cell Lung Cancer
Affiliations of authors: M. Reck, U. Gatzemeier, Department of Thoracic Oncology, Hospital Grosshansdorf, Hamburg, Germany; J. von Pawel, Asklepios Hospital, Gauting, Germany; H.-N. Macha, Lungenklinik Hemer, Hemer, Germany; E. Kaukel, Allgemeines Krankenhaus Harburg, Hamburg; K.-M. Deppermann, Fachkrankenhaus für Lungenheilkunde und Thoraxchirurgie, Berlin, Germany; R. Bonnet, Zentralklinik Bad Berka, Klinik für Pneumologie, Bad Berka, Germany; K. Ulm, Institut für Medizinische Statistik und Epidemiologie, Technical University Munich, Germany; S. Hessler, Bristol-Myers Squibb GmbH, Munich.
Correspondence to: Ulrich Gatzemeier, MD, Department of Thoracic Oncology, Hospital Grosshansdorf, Woehrendamm 80, 22927 Grosshansdorf, Hamburg, Germany (e-mail: u.gatzemeier{at}t-online.de).
Background: Paclitaxel administered in combination with a topoisomerase-II inhibitor (such as etoposide) and carboplatin is an effective and safe first-line treatment for patients with small-cell lung cancer (SCLC). We conducted a randomized phase III multicenter trial to determine whether paclitaxel plus etoposide plus carboplatin improves the outcome of patients with primary SCLC relative to standard chemotherapy (carboplatin, etoposide, and vincristine). Methods: Between January 1998 and December 1999, 614 patients with SCLC stages I–IV were randomly assigned to the standard arm (309 patients) or the experimental arm (305 patients). Treatment courses were repeated every 21 days for a maximum of six courses. All patients were evaluated for response rate, survival, and toxicities every two courses. The primary endpoint was survival. Survival curves were estimated with the Kaplan–Meier method and compared using the log-rank test. All statistical tests were two-sided. Results: A total of 608 patients were evaluable for all endpoints (standard arm 307 patients, experimental arm 301 patients). The hazard ratio [HR] of death for patients receiving the standard treatment was statistically significantly higher than that for patients receiving the experimental treatment (HR = 1.22, 95% confidence interval [CI] = 1.03 to 1.45; P = .024). Progression-free survival was also statistically significantly shorter for patients in the standard arm relative to that of patients in the experimental arm (HR = 1.21, 95% CI = 1.03 to 1.42). There were no differences in the response rates (complete and partial combined) to the treatments (standard arm: 69.4%, 95% CI = 63.9% to 74.5%; experimental arm: 72.1%, 95% CI = 66.7% to 77.1%; difference = 2.7%, 95% CI = 4.5% to 9.9%). Rates of severe grade of anemia, leukocytopenia, neutropenia, and thrombocytopenia were lower in the experimental arm than in the standard arm. Conclusion: Patients with previously untreated SCLC who received paclitaxel, etoposide, and carboplatin showed improved overall and progression-free survival and less frequent hematologic toxicities than those who received the standard therapy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Leyvraz, S. Pampallona, G. Martinelli, F. Ploner, L. Perey, S. Aversa, S. Peters, P. Brunsvig, A. Montes, A. Lange, et al. A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial J Natl Cancer Inst, April 16, 2008; 100(8): 533 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Suarez, M.-E. Jockovich, E. Hernandez, W. Feuer, J.-M. Parel, and T. G. Murray Paclitaxel in the Treatment of Retinal Tumors of LH beta-Tag Murine Transgenic Model of Retinoblastoma Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3437 - 3440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Wright, S. Bouma, I. Dayes, J. Sussman, M. R. Simunovic, M. N. Levine, and T. J. Whelan The Importance of Reporting Patient Recruitment Details in Phase III Trials J. Clin. Oncol., February 20, 2006; 24(6): 843 - 845. [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Greco, D. S. Thompson, L. H. Morrissey, J. B. Erland, H. A. Burris III, D. R. Spigel, G. Joseph, S. W. Corso, E. Spremulli, and J. D. Hainsworth Paclitaxel/Carboplatin/Etoposide Versus Paclitaxel/Topotecan for Extensive-Stage Small Cell Lung Cancer: A Minnie Pearl Cancer Research Network Randomized, Prospective Phase II Trial Oncologist, October 1, 2005; 10(9): 728 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Niell, J. E. Herndon II, A. A. Miller, D. M. Watson, A. B. Sandler, K. Kelly, R. S. Marks, M. C. Perry, R. H. Ansari, G. Otterson, et al. Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732 J. Clin. Oncol., June 1, 2005; 23(16): 3752 - 3759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Edelman, K. Chansky, L. E. Gaspar, B. Leigh, G. R. Weiss, S. A. Taylor, J. Crowley, R. Livingston, and D. R. Gandara Phase II Trial of Cisplatin/Etoposide and Concurrent Radiotherapy Followed by Paclitaxel/Carboplatin Consolidation for Limited Small-Cell Lung Cancer: Southwest Oncology Group 9713 J. Clin. Oncol., January 1, 2004; 22(1): 127 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Laskin, A. Sandler, and D. H. Johnson An Advance in Small-Cell Lung Cancer Treatment--More or Less J Natl Cancer Inst, August 6, 2003; 95(15): 1099 - 1101. [Full Text] [PDF]
|
|